Journal
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
Volume 47, Issue 3, Pages 258-267Publisher
SLACK INC
DOI: 10.3928/23258160-20160229-09
Keywords
-
Categories
Funding
- Alimera Sciences
Ask authors/readers for more resources
BACKGROUND AND OBJECTIVE: To characterize vascular endothelial growth factor (VEGF) inhibitor treatment patterns in patients with diabetic macular edema (DME) using a Medicare Standard Analytic Files Part B or Outpatient Claims database to understand treatment frequency and DME persistence. PATIENTS AND METHODS: A retrospective analysis of treatment patterns for patients diagnosed with DME receiving their first anti-VEGF injection was performed. RESULTS: The average number of anti-VEGF injection claims for DME per patient rose from 3.1 to 4.6 per year (mean: 4.2). Within 1 year of diagnosis, 46% of patients received their final DME diagnosis (mean: 1.9 anti-VEGF claims), and 65% of patients received their final anti-VEGF treatment for DME. Patients who received treatment for DME through years 2 and 3 submitted a mean of four and 7.2 anti-VEGF claims, respectively. CONCLUSION: VEGF inhibitor treatment was less frequent than in landmark trials, but did resolve DME in a proportion of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available